manidipine
Phase 2Small molecule
manidipine is one of 13 small molecule programs targeting Calcification. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Calcification
#DrugCompanyPhaseTrials
1Rocaltrol
Jazz PharmaceuticalsApproved
Eliquis
Bristol-Myers SquibbApproved
Zemplar
AbbVieApproved
Xarelto
WWim Janssens
Approved
Coumadin
AAbbott
Approved
Fosamax
OOrganon and Co
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Phoslo
VVifor Fresenius Medical Care Renal Pharma
Approved
Tums
OtsukaPreclinical
Renagel
GGenzyme, a Sanofi Company
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Calcification1 trial
Exploration of Manidipine to Reverse Aortic Valve Calcification
Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT07091136·100 enrolled
Hypertensive1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for manidipine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details